Mpox vaccine immune response under the microscope in DRC

NCT ID NCT07499739

Ongoing Knowledge-focused Sponsor: Institute of Tropical Medicine, Belgium Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 300 adults in the Democratic Republic of the Congo who received either the MVA-BN or LC16m8 mpox vaccine as part of a national campaign. Researchers collect blood samples at several time points to measure how well the vaccines trigger and maintain antibodies against the mpox virus. The goal is to understand the strength and duration of the immune response, which can help improve future vaccination efforts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MVA-BN or LC16m8 mpox vaccine
What this could lead to: If successful, this study will clarify how well these vaccines trigger and maintain immunity against mpox, guiding future vaccination strategies.
What could go wrong: This is an observational study, not a treatment trial. Results may not apply to other populations, and immune response does not guarantee protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPOX are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

monkeypox prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MPOX

Contacts and locations

Locations

Centre Convivial Kasa-Vubu

Kinshasa, Democratic Republic of the Congo
Kinoise

Kinshasa, Democratic Republic of the Congo
Kokolo

Kinshasa, Democratic Republic of the Congo

More trials for these conditions

Other studies related to the condition(s) this trial covers.